Inverse agonist properties of atypical antipsychotic drugs

Biochemical Pharmacology

Volumn 67, Issue 11, 2004, Pages 2039-2045

  Akam, Elizabeth ^a   Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

(+) UH 232; Atypical antipsychotic drugs; cAMP; cis (+) 5 methoxy 1 methyl 2 (di N propylamino)tetralin; D2 dopamine receptor; D2 receptor; DMEM; Dulbecco's modified Eagle's medium; Inverse agonism

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; ATYPICAL ANTIPSYCHOTIC AGENT; BUTACLAMOL; CLOZAPINE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FORSKOLIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; SODIUM ION;

AGONIST; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SCREENING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BUTACLAMOL; CHO CELLS; CLOZAPINE; CRICETINAE; CYCLIC AMP; DRUG INTERACTIONS; FEMALE; FORSKOLIN; HUMANS; RECEPTORS, DOPAMINE D2; RISPERIDONE; SODIUM;

EID: 2342530853     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.017     Document Type: Article

References (33)

1. Leysen JE, Niemegeers CJE. Neuroleptics. Handbook of neurochemistry, vol. 9; 1985. p. 331-61.
2. Strange PG. Brain biochemistry and brain disorders. Oxford: OUP; 1992.
3. Gelder M, Gath D, Mayou R, Cowan P. Oxford textbook of psychiatry. 3rd ed. Oxford, UK: Oxford University Press; 1996.
4. Lidow M.S., Williams G.V., Goldman-Rakic P.S. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci. 19:1998;136-140
5. Kane J.M. What makes an antipsychotic atypical? Should the definition be preserved. CNS Drugs. 7:1997;347-348
6. Waddington J.L., O'Callaghan E. What makes an antipsychotic atypical? Conserving the definition. CNS Drugs. 7:1997;341-346
7. Remington G., Kapur S Atypical antipsychotics: are some more atypical than others. Psychopharmacology. 148:2000;3-15
8. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:1994;264-269
9. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53:2001;119-133
10. 2 receptors. J. Neural Trans. 92:1993;213-220
11. Wiens B.L., Nelson C.S., Neve K.A. Contribution of serine residues to constitutive and agonist-induced signalling via the D2s dopamine receptor: evidence for multiple, agonist specific active conformations. Mol. Pharmacol. 54:1998;435-444
12. 3 dopamine receptor. J. Neural. Trans. 103:1996;1163-1175
13. 2 dopamine receptors. Br. J. Pharmacol. 121:1997;731-736
14. 1 dopamine receptor. Mol. Pharmacol. 52:1997;1137-1149
15. 2 dopamine receptor that adopts the activated conformation. J. Neurochem. 77:2001;493-504
16. Wurch T., Boutenet-Robinet E.A., Palmier C., Colpaert F.C., Pauwels P.J. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs. J. Pharmacol. Exp. Ther. 304:2003;380-390
17. Johansson A.M., Arvidsson L.E., Hacksell U., Nilsson J.L., Svensson K., Carlsson A. Resolved cis- and trans-2-amino-5-methoxy-1-methyltetralins: central dopamine receptor agonists and antagonists. J Med Chem. 30:1987;602-611
18. Griffon N., Pilon C., Schwartz J.C., Sokoloff P. The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist. Eur. J. Pharmacol. 282:1995;R3-R4
19. 4.4 receptors expressed in CHO cells. Br. J. Pharmacol. 127:1999;1135-1144
20. Pauwels P.J., Finana F., Tardif S., Wurch T., Colpaert F.C. Dynamic dopamine-antagonist interactions at recombinant human dopamine D(2short) receptor: dopamine-bound versus antagonist-bound receptor states. J. Pharmacol. Exp. Ther. 297:2001;133-140
21. Milligan G., Bond R.A. Inverse agonism and the regulation of receptor number. Trends Pharmacol. Sci. 18:1997;468-474
22. Leurs R., Smit M., Alewijnse A.E., Timmerman H. Agonist independent regulation of constitutively active G protein coupled receptors. Trends Biochem. Sci. 23:1998;418-422
23. De Ligt R.A.F., Kourounakis A.P., Ijzerman A.P. Inverse agonism at G protein coupled receptors: (patho)physiological relevance and implications for drug discovery. Br. J. Pharmacol. 130:2000;1-12
24. Strange P.G. Mechanisms of inverse agonism at G protein coupled receptors. Trends Pharmacol. Sci. 23:2002;89-95
25. Lefkowitz R.J., Cotecchia S., Samama P., Costa T Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14:1993;303-307
26. 3H ]spiperone to rat striatal preparations J. Pharm. Pharmacol. 32:1980;441-444
27. 3H ]YM-09151-2 Naunyn Schmiedebergs Arch. Pharmacol. 329:1985;333-343
28. 2 dopamine receptors by sodium and pH. Mol. Pharmacol. 39:1991;570-578
29. 2 dopamine receptor/G protein interaction: evidence for agonist selection of G protein subtype. J. Biol. Chem. 276:2001;28667-28675
30. 2 dopamine receptor. J. Neurochem. 60:1993;372-375
31. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58:1974;541-548
32. Lahti A.C., Weiler M., Carlsson A., Tamminga C.A. Effects of the D-3 and autoreceptor preferring dopamine antagonist (+)-UH 232 in schizophrenia. J. Neural Trans. 105:1998;719-734
33. 2 receptors. J. Pharmacol. Exp. Ther. 302:2002;381-389